Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Site, OBI Investigator
NCT03562637: Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC	Recruiting	3	668	Europe, US, RoW	adagloxad simolenin combined with OBI-821, Globo H IHC Assay, Standard of care treatment	OBI Pharma, Inc	Triple Negative Breast Cancer	12/25	12/27
NCT03592264: A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors	Terminated	1/2	68	US	OBI-3424	OBI Pharma, Inc	Solid Tumor, Pancreatic Adenocarcinoma	02/24	03/24